Porth Ymchwil

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

StandardStandard

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. / Hughes, D.; Faulkner, E.; Annemans, L. et al.
Yn: Value in Health, Cyfrol 15, Rhif 8, 01.12.2012, t. 1162-1171.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

HarvardHarvard

Hughes, D, Faulkner, E, Annemans, L, Garrison, L, Helfand, M, Holtorf, AP, Hornberger, J, Hughes, DA, Li, T, Malone, D, Payne, K, Siebert, U, Towse, A, Veenstra, D & Watkins, J 2012, 'Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group', Value in Health, cyfrol. 15, rhif 8, tt. 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

APA

Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D., & Watkins, J. (2012). Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 15(8), 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

CBE

Hughes D, Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes DA, Li T, Malone D, et al. 2012. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 15(8):1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

MLA

Hughes, D. et al. "Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group". Value in Health. 2012, 15(8). 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

VancouverVancouver

Hughes D, Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012 Rhag 1;15(8):1162-1171. doi: 10.1016/j.jval.2012.05.006

Author

Hughes, D. ; Faulkner, E. ; Annemans, L. et al. / Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Yn: Value in Health. 2012 ; Cyfrol 15, Rhif 8. tt. 1162-1171.

RIS

TY - JOUR

T1 - Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

AU - Hughes, D.

AU - Faulkner, E.

AU - Annemans, L.

AU - Garrison, L.

AU - Helfand, M.

AU - Holtorf, A.P.

AU - Hornberger, J.

AU - Hughes, D.A.

AU - Li, T.

AU - Malone, D.

AU - Payne, K.

AU - Siebert, U.

AU - Towse, A.

AU - Veenstra, D.

AU - Watkins, J.

PY - 2012/12/1

Y1 - 2012/12/1

U2 - 10.1016/j.jval.2012.05.006

DO - 10.1016/j.jval.2012.05.006

M3 - Article

VL - 15

SP - 1162

EP - 1171

JO - Value in Health

JF - Value in Health

SN - 1524-4733

IS - 8

ER -